Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue Estimates

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue estimate for the current year.

Neogen (NASDAQ: NEOG) is likely to post revenue of $235.22 million in the year ending May, 2014. Neogen's PEG ratio is 2.85.

Analysts expect Meridian Bioscience (NASDAQ: VIVO) to post revenue of $204.53 million for the year ending September, 2014. Meridian Bioscience's trailing-twelve-month ROE is 25.63%.

Quidel (NASDAQ: QDEL) is expected to report revenue of $173.74 million for the year ending December, 2013. Quidel had $10.25 million in total cash for the latest quarter.

Abaxis (NASDAQ: ABAX) may report revenue of $188.65 million in the year ending March, 2014. Abaxis's trailing-twelve-month operating margin is 14.31%.